Citation

Milliken E, Galettis P, Martin J, Milliken E, Galettis P, Martin J. Aust. J. Chem. 2023; 76(5): 258-263.

Copyright

(Copyright © 2023, Commonwealth Scientific And Industrial Research Organization)

DOI

10.1071/CH23010

PMID

unavailable

Abstract

Classic psychedelics such as psilocybin, ketamine and lysergic acid diethylamide (LSD) are 5HT2A serotonin receptor agonists that produce individualised subjective affects. Today, public interest in psychedelic medicine has reached a fervour but the evidence for clinical benefit still lags. Psilocybin and psilocin are tryptophan based alkaloids found worldwide in mushrooms of the genera Psilocybe, Panaeolus, Conocybe, Gymnopilus, Stropharia, Pluteus and Panaeolina. This review addresses the current evidence base for psilocybin as a clinical medicine, the general chemistry and proposed mechanism of its therapeutic effect and future research directions for psilocybin based therapies.

Language: en